HUP0102812A2 - Foszfolipáz inhibitor hatású nátrium-{[3-(2-amino-1,2-dioxoetil)-2-etil-1-(fenilmetil)-1H-indol-4-il]oxi}acetátot tartalmazó gyógyászati készítmények és eljárás előállításukra - Google Patents

Foszfolipáz inhibitor hatású nátrium-{[3-(2-amino-1,2-dioxoetil)-2-etil-1-(fenilmetil)-1H-indol-4-il]oxi}acetátot tartalmazó gyógyászati készítmények és eljárás előállításukra

Info

Publication number
HUP0102812A2
HUP0102812A2 HU0102812A HUP0102812A HUP0102812A2 HU P0102812 A2 HUP0102812 A2 HU P0102812A2 HU 0102812 A HU0102812 A HU 0102812A HU P0102812 A HUP0102812 A HU P0102812A HU P0102812 A2 HUP0102812 A2 HU P0102812A2
Authority
HU
Hungary
Prior art keywords
pruducing
dioxoethyl
phenylmethyl
indol
oxy
Prior art date
Application number
HU0102812A
Other languages
English (en)
Inventor
William Lester Confer
Hideaki Tai
Original Assignee
Eli Lilly And Co.
Shionogi & Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Co., Shionogi & Co., Ltd. filed Critical Eli Lilly And Co.
Publication of HUP0102812A2 publication Critical patent/HUP0102812A2/hu
Publication of HUP0102812A3 publication Critical patent/HUP0102812A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HU0102812A 1998-03-03 1999-03-02 Pharmaceutical compositions containing the phospholipase inhibitor sodium {[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1h-indol-4-yl]oxy}acetate and process for pruducing them HUP0102812A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7665998P 1998-03-03 1998-03-03
PCT/US1999/004516 WO1999044604A1 (en) 1998-03-03 1999-03-02 Pharmaceutical compositions containing the phospholipase inhibitor sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate

Publications (2)

Publication Number Publication Date
HUP0102812A2 true HUP0102812A2 (hu) 2001-12-28
HUP0102812A3 HUP0102812A3 (en) 2002-01-28

Family

ID=22133426

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102812A HUP0102812A3 (en) 1998-03-03 1999-03-02 Pharmaceutical compositions containing the phospholipase inhibitor sodium {[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1h-indol-4-yl]oxy}acetate and process for pruducing them

Country Status (21)

Country Link
US (1) US6166062A (hu)
EP (1) EP1058547B1 (hu)
JP (3) JP2002505282A (hu)
KR (1) KR20010034552A (hu)
CN (1) CN1299277A (hu)
AT (1) ATE310513T1 (hu)
AU (1) AU757002B2 (hu)
BR (1) BR9908479A (hu)
CA (1) CA2322796A1 (hu)
DE (1) DE69928500T2 (hu)
EA (1) EA003864B1 (hu)
ES (1) ES2253877T3 (hu)
HU (1) HUP0102812A3 (hu)
ID (1) ID27487A (hu)
IL (1) IL138154A0 (hu)
NO (1) NO20004306L (hu)
NZ (1) NZ506578A (hu)
PL (1) PL342822A1 (hu)
TR (1) TR200002543T2 (hu)
TW (1) TW570795B (hu)
WO (1) WO1999044604A1 (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001236440A1 (en) * 2000-01-25 2001-08-07 Eli Lilly And Company Method for the treatment of inflammation with spla2 inhibitors
JP2003525901A (ja) * 2000-03-09 2003-09-02 イーライ・リリー・アンド・カンパニー ｓＰＬＡ２インヒビターによる腎臓機能障害の治療方法
WO2002005796A2 (en) * 2000-07-14 2002-01-24 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
TWI232102B (en) 2001-07-17 2005-05-11 Shionogi & Co A pharmaceutical formulation for injection
CN1568999A (zh) * 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
MXPA06012777A (es) * 2004-05-06 2007-02-14 Cydex Inc Formulaciones de sabor enmascarado que contienen sertralina y eter sulfoalquilico-ciclodextrina.
TWI520735B (zh) * 2006-06-09 2016-02-11 史華茲製藥公司 含菲索特羅定之安定化醫藥組成物
RU2009134128A (ru) * 2007-02-12 2011-03-20 Лассаад БУЖБЕЛЬ (TN) Сукралоза в стерильном растворе без консервантов
JP5174365B2 (ja) * 2007-03-23 2013-04-03 第一三共株式会社 キノロン含有凍結乾燥製剤の製造方法
EP2106788A1 (en) * 2008-04-04 2009-10-07 Ipsen Pharma Liquid and freeze dried formulations
EP3563842A1 (en) 2009-04-29 2019-11-06 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
KR20140053952A (ko) * 2011-08-26 2014-05-08 제이더블유중외제약 주식회사 피라지노-트리아진 유도체를 포함하는 조성물
EP2923710A1 (en) 2014-03-27 2015-09-30 Universitätsklinikum Heidelberg Bacterial phospholipase inhibitors as modulator of colonic bacterial flora

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO873860L (no) * 1986-10-31 1988-05-02 Asta Pharma Ag Ifosfamid-lyofilisat og fremgangsmaate til deres fremstilling.
JPH02207092A (ja) * 1989-02-07 1990-08-16 Kirin Brewery Co Ltd アンスラサイクリン化合物またはその塩の凍結乾燥製剤の製造法
JP3999263B2 (ja) * 1993-10-27 2007-10-31 ファルマシア・アンド・アップジョン・カンパニー 安定化したプロスタグランジンｅ▲１▼
AU688458B2 (en) * 1994-04-01 1998-03-12 Eli Lilly And Company 1H-indole-3-glyoxylamide sPLA2 inhibitors

Also Published As

Publication number Publication date
JP2006096761A (ja) 2006-04-13
NZ506578A (en) 2003-09-26
JP2011021042A (ja) 2011-02-03
DE69928500T2 (de) 2006-08-03
ID27487A (id) 2001-04-12
AU757002B2 (en) 2003-01-30
WO1999044604A9 (en) 2000-01-20
IL138154A0 (en) 2001-10-31
BR9908479A (pt) 2000-12-05
EP1058547A1 (en) 2000-12-13
KR20010034552A (ko) 2001-04-25
CN1299277A (zh) 2001-06-13
ES2253877T3 (es) 2006-06-01
JP2002505282A (ja) 2002-02-19
TW570795B (en) 2004-01-11
EA003864B1 (ru) 2003-10-30
NO20004306D0 (no) 2000-08-29
US6166062A (en) 2000-12-26
EP1058547B1 (en) 2005-11-23
AU2799899A (en) 1999-09-20
PL342822A1 (en) 2001-07-02
DE69928500D1 (de) 2005-12-29
EA200000897A1 (ru) 2001-02-26
NO20004306L (no) 2000-10-10
CA2322796A1 (en) 1999-09-10
HUP0102812A3 (en) 2002-01-28
TR200002543T2 (tr) 2000-11-21
WO1999044604A1 (en) 1999-09-10
ATE310513T1 (de) 2005-12-15

Similar Documents

Publication Publication Date Title
HUP0100156A3 (en) Indole derivatives as inhibitors of phospholipase a2 and use of them for producing pharmaceutical compositions
IS6254A (is) Lyfjasamsetningar sem innihalda HMG afoxunarensímlata
HUP0101146A3 (en) Indole derivatives as inhibitors of phospholipase enzymes and pharmaceutical compositions containing them
HUP0100757A3 (en) Indole derivatives as inhibitors of phospholipase enzymes and pharmaceutical compositions containing them
HK1048589A1 (zh) 促進生長的含二肽基肽酶iv抑制劑的藥物組合物
HUP0103633A2 (hu) Szubsztituált 3-cianokinolinok mint protein tirozin kinázok inhibitorai, eljárás a vegyületek előállítására és a vegyületeket tartalmazó gyógyászati készítmények
HUP0102812A3 (en) Pharmaceutical compositions containing the phospholipase inhibitor sodium {[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1h-indol-4-yl]oxy}acetate and process for pruducing them
HUP0004120A3 (en) Use of cgmp-pde5 inhibitors for the preparation of pharmaceutical compositions treating neuropathy
AU2001268154A1 (en) Indolinone derivatives as protein kinase/phosphatase inhibitors
HUP0104987A3 (en) Benzimidazole or indole derivatives protease inhibitors, and pharmaceutical compositions containing them
HUP0302485A3 (en) Arylmethylamine derivatives for use as tryptase inhibitors and pharmaceutical compositions containing them
HUP0203122A3 (en) Fab i inhibitors, process for their preparation, pharmaceutical compositions containing them and their use
HUP0303146A3 (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors and pharmaceutical compositions containing them
AU1928501A (en) Formulations for pharmaceutical agents ionizable as free acids or free bases
HUP0103452A3 (en) Hydroxy pipecolate hydroxamic acid derivatives as mmp inhibitors and pharmaceutical compositions containing the compounds
HUP0101281A3 (en) Diphenyl-piperidine butanamides as glycine transport inhibitors, process for producing them, use of them for producing medicaments and the pharmaceutical compositions containing them
IL143979A0 (en) Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
ZA973647B (en) Inhibitors of metalloprotease, process for preparing them and pharmaceutical compositions containing them.
HUP0204157A3 (en) 1,3-dihydro-2h-indol-2-one derivatives, process for preparation of the compounds and pharmaceutical compositions containing the same
HUP0102922A3 (en) 2,3-substituted indole compounds as cox-2 inhibitors, process for producing them and pharmaceutical compositions containing them
HUP0203597A3 (en) Pharmaceutical compositions containing zolmitriptan, process for their preparation and their use
HUP0204585A3 (en) Ox(adi)azolyl-hydroxamic acids useful as procollagen c-proteinase inhibitors, process for their preparation and pharmaceutical compositions containing them
HUP9801950A3 (en) 2-(arylphenyl-amino)-imidazoline derivatives, process for producing them and pharmaceutical compositions containing them
GB0031145D0 (en) Compounds that effect cd83 expression pharmaceutical compositions comprising said compounds and methods for identifying said compounds
HUP0105308A3 (en) Eletriptan hydrobromide monohydrate, process for its preparation and pharmaceutical compositions containing the same